tirzepatide: the established option offers certainty, while the newer one carries more potential but also more unknowns
Module 1 establishes this mechanistic case, defines the three levels of GLP-1 RA use, and introduces microdosing as a longevity lever: a targeted intervention that preserves muscle, reduces inflammation, and supports long-term metabolic health at doses well below standard therapeutic thresholds
The conversations with your medical team should include: What proportion of weight lost is fat versus lean muscle mass
This coincides with the FDA approval of the first CFTR modulator in 2012 (ivacaftor [Kalydeco]), followed by dual therapy in 2015 and 2018 (lumacaftor/ivacaftor [Orkambi] and tezacaftor/ivacaftor [Symdeko], respectively), and the first triple therapy in 2019 (Trikafta)
GLP-1 agonists help your body make more of the hormone GLP-1 (glucagon-like peptide 1)
Make protein your first priority